Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 714.47 -0.66 (-0.09%) Market Cap: 78.51 Bil Enterprise Value: 71.42 Bil PE Ratio: 17.68 PB Ratio: 2.68 GF Score: 88/100

Regeneron Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 12:10PM GMT
Release Date Price: $279 (-4.45%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Great. Good morning, everybody. Thanks for joining us for the first session which we'll kick off with Regeneron. I'm Matthew Harrison, one of the biotech analysts here. Before we start, I have to read an important disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley discloses, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up a copy at the registration desk.

And so with that, we can get down to business. So happy to have with me from Regeneron, Marion McCourt, who runs commercial; and Jay Markowitz, who is SVP of Portfolio Management.

Questions & Answers

Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

So I thought to start off, we would try and just address some of the overriding topics that investors have around Regeneron and then maybe we could spend some time on EYLEA as well as some of the other

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot